Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety With Echocardiographic Contrast Agents.

Preetham R Muskula1, Michael L Main2

  • 1From Saint Luke's Mid America Heart Institute, Kansas City, MO.

Circulation. Cardiovascular Imaging
|April 6, 2017
PubMed
Summary

Echocardiographic contrast agents (ECA) like Definity and Optison have undergone safety reviews following adverse events. Updated labeling and ongoing research clarify ECA safety in various patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Ambient AI Could Bring the Human Touch Back to Medicine.

Missouri medicine·2026
Same author

Contemporary Safety of Ultrasound Enhancing Agents in a Nationwide Analysis.

Journal of the American Heart Association·2025
Same author

Multi-societal expert consensus statement on the safe administration of ultrasound contrast agents.

Echo research and practice·2025
Same author

Illuminating the Safety of Ultrasound Contrast Agents.

The American journal of cardiology·2024
Same author

Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.

JACC. Cardiovascular interventions·2023
Same author

CEUS cardiac exam protocols International Contrast Ultrasound Society (ICUS) recommendations.

Echo research and practice·2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Echocardiographic contrast agents (ECA) like Definity and Optison faced revised labeling in 2007 due to reported cardiopulmonary reactions and deaths.
  • Subsequent large-scale studies have investigated ECA safety across diverse patient populations, including critically ill and those with pulmonary hypertension.

Purpose of the Study:

  • To review the safety profile of echocardiographic contrast agents (ECA) in specific patient cohorts.
  • To examine the impact of regulatory actions and evolving research on ECA safety guidelines.

Main Methods:

  • Review of post-marketing surveillance data and published safety studies on Definity and Optison.
  • Analysis of Food and Drug Administration (FDA) Advisory Committee meeting outcomes and label revisions.
Keywords:
contrast mediaechocardiographyechocardiography, stressproduct labelingpulmonary heart disease

Related Experiment Videos

  • Synthesis of evidence regarding ECA use in patients with cardiopulmonary conditions, shunts, and special populations.

    • Main Results:

    • Evolving research and regulatory reviews have led to revised safety restrictions for Definity and Optison.
    • Studies have assessed ECA safety in outpatient, inpatient, critically ill, stress echocardiography, and pulmonary hypertension settings.
    • The role of pseudocomplications in adverse event attribution and the current status of the ECA Black Box Warning are discussed.

    Conclusions:

    • Evolving data supports a nuanced understanding of echocardiographic contrast agent safety.
    • Recommendations for safe administration in various clinical scenarios, including special populations, are crucial.
    • Continued vigilance and adherence to updated guidelines are necessary for optimal patient outcomes.